AllazoHealth, a leader in AI-driven solutions for enhancing therapy initiation, adherence, and health outcomes, today announced the release of a compelling case study showcasing its partnership with a top 10 rare disease pharmaceutical company. The study details the significant improvements achieved through AI-enabled personalized communication strategies, which increased therapy initiation by 10.4% and reduced therapy discontinuation by 7.3%.

The pharma company sought to revolutionize its patient support programs by providing a more tailored experience across multiple administration methods, including clinic infusion, home infusion, self-injection, and oral medications. Historically reliant on live nurse calls for high-touch support, the company aimed to improve the patient journey while reducing the cost and intensity of support efforts. With AllazoHealth’s AI-driven personalization, approximately 10,000 patients received optimized, multi-channel communication strategies tailored to enhance onboarding, medication adherence, and physician follow-ups.

The partnership leveraged AI to provide a daily, data-informed approach to patient engagement. The AI’s algorithms informed and customized every interaction with patients, caregivers, prescribers, and infusion centers, optimizing each outreach based on:

• Prioritization of communication efforts
• Optimal timing of outreach
• Frequency and number of contact attempts
• Selection of relevant content and messaging
• Decision-making to cancel pending communications when appropriate

This personalized approach led to outstanding results, with more patients initiating and adhering to therapy. Qualitative feedback from the pharma company’s leadership underscored the value of AI in shaping a better patient experience and enabling a more impactful role for their nurse support team. According to one executive, “Patients benefited from the experience and nurse specialists experienced greater success in achieving their mission to engage patients and make a meaningful difference in their lives.”

“Great Investment in Health Outcomes”
Reflecting on the success, William Grambley, CEO of AllazoHealth, said, “The results of this collaboration went beyond our initial targets, helping reduce non-actionable therapy discontinuations and boosting therapy initiation. Our AI-based approach accurately predicted individual patient needs and optimized the timing and content of communications, which drove better health outcomes. This case study highlights how AI personalization is an essential tool for modern patient support programs.”

This case study underscores AllazoHealth’s impact in personalizing the patient journey, reducing healthcare costs, and improving health outcomes.

Case Study: AllazoHealth Partners with Top 10 Rare Diseases Pharma Company – AI-Based Targeted, Personalized Communications Boosts Initiation and Adherence